Citadel Advisors’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-317,628
| Closed | -$788K | – | 13942 |
|
|
2025
Q4 | $572K | Buy |
317,628
+280,322
| +751% | +$573K | ﹤0.01% | 8703 |
|
|
2025
Q3 | $82.8K | Buy |
+37,306
| New | +$60.8K | ﹤0.01% | 11953 |
|
|
2025
Q2 | – | Sell |
-2,818
| Closed | -$5.76K | – | 14493 |
|
|
2025
Q1 | $7.21K | Sell |
2,818
-142,969
| -98% | -$341K | ﹤0.01% | 13699 |
|
|
2024
Q4 | $274K | Buy |
145,787
+54,129
| +59% | +$76.5K | ﹤0.01% | 9837 |
|
|
2024
Q3 | $93.5K | Buy |
91,658
+73,190
| +396% | +$77K | ﹤0.01% | 11213 |
|
|
2024
Q2 | $21.6K | Sell |
18,468
-19,320
| -51% | -$22.8K | ﹤0.01% | 12562 |
|
|
2024
Q1 | $47.6K | Buy |
+37,788
| New | +$56.4K | ﹤0.01% | 12218 |
|
|
2023
Q4 | – | Sell |
-25,614
| Closed | -$39.8K | – | 15008 |
|
|
2023
Q3 | $42.5K | Buy |
+25,614
| New | +$46K | ﹤0.01% | 11939 |
|
|
2023
Q2 | – | Sell |
-211,548
| Closed | -$504K | – | 15033 |
|
|
2023
Q1 | $444K | Buy |
211,548
+87,241
| +70% | +$153K | ﹤0.01% | 8552 |
|
|
2022
Q4 | $170K | Buy |
124,307
+65,750
| +112% | +$72.1K | ﹤0.01% | 10404 |
|
|
2022
Q3 | $61K | Sell |
58,557
-1,358
| -2% | -$1.5K | ﹤0.01% | 11491 |
|
|
2022
Q2 | $65K | Buy |
+59,915
| New | +$70.1K | ﹤0.01% | 11763 |
|
|
2022
Q1 | – | Sell |
-29,015
| Closed | -$26.6K | – | 14349 |
|
|
2021
Q4 | $24K | Buy |
29,015
+4,070
| +16% | +$4.26K | ﹤0.01% | 13547 |
|
|
2021
Q3 | $34K | Sell |
24,945
-90,941
| -78% | -$138K | ﹤0.01% | 13527 |
|
|
2021
Q2 | $221K | Buy |
115,886
+100,114
| +635% | +$345K | ﹤0.01% | 11942 |
|
|
2021
Q1 | $70K | Buy |
+15,772
| New | +$73.4K | ﹤0.01% | 12732 |
|
|
2020
Q3 | – | Sell |
-24,047
| Closed | -$87K | – | 10591 |
|
|
2020
Q2 | $92K | Buy |
+24,047
| New | +$82.2K | ﹤0.01% | 9036 |
|
|
2019
Q4 | – | Sell |
-1,581
| Closed | -$3K | – | 9599 |
|
|
2019
Q3 | $3K | Sell |
1,581
-5,562
| -78% | -$16.6K | ﹤0.01% | 9079 |
|
|
2019
Q2 | $34K | Buy |
7,143
+4,516
| +172% | +$19.1K | ﹤0.01% | 8838 |
|
|
2019
Q1 | $12K | Buy |
2,627
+205
| +8% | +$924 | ﹤0.01% | 9138 |
|
|
2018
Q4 | $8K | Sell |
2,422
-878
| -27% | -$4.17K | ﹤0.01% | 8956 |
|
|
2018
Q3 | $24K | Sell |
3,300
-5,912
| -64% | -$29.7K | ﹤0.01% | 8980 |
|
|
2018
Q2 | $40K | Buy |
9,212
+7,281
| +377% | +$32.4K | ﹤0.01% | 8484 |
|
|
2018
Q1 | $10K | Buy |
+1,931
| New | +$12.7K | ﹤0.01% | 8182 |
|
|
2017
Q2 | – | Sell |
-10,250
| Closed | -$96.2K | – | 7924 |
|
|
2017
Q1 | $139K | Buy |
10,250
+6,518
| +175% | +$58.6K | ﹤0.01% | 6724 |
|
|
2016
Q4 | $17K | Buy |
+3,732
| New | +$16.7K | ﹤0.01% | 7112 |
|
|
2016
Q3 | – | Sell |
-1,068
| Closed | -$7K | – | 7627 |
|
|
2016
Q2 | $7K | Sell |
1,068
-1,586
| -60% | -$12.7K | ﹤0.01% | 6743 |
|
|
2016
Q1 | $22K | Buy |
2,654
+900
| +51% | +$7.71K | ﹤0.01% | 6441 |
|
|
2015
Q4 | $18K | Buy |
1,754
+1,427
| +436% | +$14.5K | ﹤0.01% | 8006 |
|
|
2015
Q3 | $4K | Buy |
327
+296
| +955% | +$4.71K | ﹤0.01% | 8666 |
|
|
2015
Q2 | $1K | Sell |
31
-472
| -94% | -$9.79K | ﹤0.01% | 8649 |
|
|
2015
Q1 | $9K | Sell |
503
-4,342
| -90% | -$85K | ﹤0.01% | 8220 |
|
|
2014
Q4 | $89K | Buy |
+4,845
| New | +$104K | ﹤0.01% | 6740 |
|
|
2014
Q3 | – | Sell |
-1,014
| Closed | -$29.2K | – | 8335 |
|
|
2014
Q2 | $37K | Sell |
1,014
-513
| -34% | -$20.7K | ﹤0.01% | 6948 |
|
|
2014
Q1 | $70K | Sell |
1,527
-507
| -25% | -$23.7K | ﹤0.01% | 6493 |
|
|
2013
Q4 | $79K | Buy |
2,034
+1,890
| +1,313% | +$79.6K | ﹤0.01% | 5779 |
|
|
2013
Q3 | $7K | Sell |
144
-1,472
| -91% | -$75.6K | ﹤0.01% | 6531 |
|
|
2013
Q2 | $79K | Buy |
+1,616
| New | +$85.7K | ﹤0.01% | 5392 |
|
Other funds holding PLX
MCO
SWP
VPM
PFS
OM
Citadel Advisors's PLX Position: Q1 2026 in Review
Citadel Advisors sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 317,628 shares — an estimated $788K sold.
Citadel Advisors first reported a position in PLX in Q2 2013 and held it in 38 quarters. The position peaked at $572K in Q4 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.
- Citadel Advisors reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 317,628 Protalix BioTherapeutics shares in Q1 2026, an estimated $788K.
- Citadel Advisors first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 38 quarters.
- Citadel Advisors's Protalix BioTherapeutics position peaked at $572K in Q4 2025.
- 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.